[go: up one dir, main page]

ES2067418A1 - New application of recombinant human interleukin-1 beta in the ophthalmology field - Google Patents

New application of recombinant human interleukin-1 beta in the ophthalmology field

Info

Publication number
ES2067418A1
ES2067418A1 ES09301611A ES9301611A ES2067418A1 ES 2067418 A1 ES2067418 A1 ES 2067418A1 ES 09301611 A ES09301611 A ES 09301611A ES 9301611 A ES9301611 A ES 9301611A ES 2067418 A1 ES2067418 A1 ES 2067418A1
Authority
ES
Spain
Prior art keywords
beta
recombinant human
new application
human interleukin
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09301611A
Other languages
Spanish (es)
Other versions
ES2067418B1 (en
Inventor
Jimeno Jose Carlos Pastor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Valladolid
Original Assignee
Universidad de Valladolid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Valladolid filed Critical Universidad de Valladolid
Priority to ES9301611A priority Critical patent/ES2067418B1/en
Publication of ES2067418A1 publication Critical patent/ES2067418A1/en
Application granted granted Critical
Publication of ES2067418B1 publication Critical patent/ES2067418B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

New application of recombinant human interleukin-1 beta in the ophthalmology field. Recombinant human interleukin-1 beta has applications as a drug for the treatment of human intravitreous haemorrhages, which are an important cause of blindness. The aforesaid interleukin also has applications in the manufacture of drugs for the treatment of said haemorrhages in the form of intravitreous injections, intended to be administered by the transconjunctival route, with an interleukin dose of 1,000 biological units at most.
ES9301611A 1993-07-16 1993-07-16 NEW APPLICATION OF INTERLEUKINA-1 BETA RECOMBINANT HUMAN IN THE FIELD OF OPHTHALMOLOGY. Expired - Fee Related ES2067418B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9301611A ES2067418B1 (en) 1993-07-16 1993-07-16 NEW APPLICATION OF INTERLEUKINA-1 BETA RECOMBINANT HUMAN IN THE FIELD OF OPHTHALMOLOGY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9301611A ES2067418B1 (en) 1993-07-16 1993-07-16 NEW APPLICATION OF INTERLEUKINA-1 BETA RECOMBINANT HUMAN IN THE FIELD OF OPHTHALMOLOGY.

Publications (2)

Publication Number Publication Date
ES2067418A1 true ES2067418A1 (en) 1995-03-16
ES2067418B1 ES2067418B1 (en) 1995-11-01

Family

ID=8282586

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9301611A Expired - Fee Related ES2067418B1 (en) 1993-07-16 1993-07-16 NEW APPLICATION OF INTERLEUKINA-1 BETA RECOMBINANT HUMAN IN THE FIELD OF OPHTHALMOLOGY.

Country Status (1)

Country Link
ES (1) ES2067418B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054589A1 (en) * 2002-12-13 2004-07-01 Arturo Jimenez Bayardo Intravitreally-injectable solution for the treatment of vitreous haemorrhages

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
WO1990012590A1 (en) * 1989-04-14 1990-11-01 State Of Oregon, State Board Of Higher Education, Oregon Health Sciences University Treatment of ocular disease by modulation of matrix metalloproteinases and their inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
WO1990012590A1 (en) * 1989-04-14 1990-11-01 State Of Oregon, State Board Of Higher Education, Oregon Health Sciences University Treatment of ocular disease by modulation of matrix metalloproteinases and their inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OPHTALMIC RESEARCH, Vol. 25 (5), 1993; J.C. PASTOR y C. FERNANDEZ: "Efficacy of intravenous interleukin-1 in the reabsortion of experimental vitreous hemorrhage in rabbits" pßg. 3302-3306 * Todo el documento * *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054589A1 (en) * 2002-12-13 2004-07-01 Arturo Jimenez Bayardo Intravitreally-injectable solution for the treatment of vitreous haemorrhages

Also Published As

Publication number Publication date
ES2067418B1 (en) 1995-11-01

Similar Documents

Publication Publication Date Title
DE69333321T2 (en) Use of a consensus interferon to reduce the side effects in the interferon treatment of viral hepatites.
EP0693924A4 (en) METHODS FOR -i(IN VIVO) DELIVERY OF BIOLOGICS AND COMPOSITIONS USEFUL THEREFOR
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
CA2031430A1 (en) Process for refolding recombinantly produced tgf-.beta.-like proteins
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
AU7405387A (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
EP0850648A3 (en) Combination of thrombolytically active proteins and anticoagulants and uses thereof
DE69628163D1 (en) NOR-PREGNANE FOR INDUCING HYPOTHALAMIC EFFECTS
ATE243196T1 (en) PIPERIDINE AND PYRROLIDINE
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
NZ335003A (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
GR3019171T3 (en) System for delivering drug with enhanced bioacceptability.
FI953565A7 (en) New anticoagulant cofactor activity
KR910700069A (en) Treatment of Leukocyte Dysfunction Using GM-CSF
EP0363083A3 (en) Pharmaceutical preparation for treatment of thrombocytopenic or platelet function-deficient disease
ES2067418A1 (en) New application of recombinant human interleukin-1 beta in the ophthalmology field
EA200200801A1 (en) Use of follicle-stimulating hormone (FSH) for the treatment of infertility
ATE222768T1 (en) CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 TO TREAT INFECTIONS
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
KR900701311A (en) How to treat squamous cell carcinoma by administering recombinant human α-interferon intralesionally
KR920014480A (en) Use of a polypeptide having activity of human interleukin 2 to prepare a pharmaceutical composition for treating pneumothorax
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20141120